News Column

Studies from University of California Add New Findings in the Area of Stem Cells (Mesenchymal Stem Cell Population Derived from Human Pluripotent...

August 20, 2014



Studies from University of California Add New Findings in the Area of Stem Cells (Mesenchymal Stem Cell Population Derived from Human Pluripotent Stem Cells Displays Potent Immunomodulatory and Therapeutic Properties)

By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Stem Cell Research. According to news reporting originating from Los Angeles, California, by NewsRx correspondents, research stated, "Mesenchymal stem cells (MSCs) are being tested in a wide range of human diseases; however, loss of potency and inconsistent quality severely limit their use. To overcome these issues, we have utilized a developmental precursor called the hemangioblast as an intermediate cell type in the derivation of a highly potent and replenishable population of MSCs from human embryonic stem cells (hESCs)."

Our news editors obtained a quote from the research from the University of California, "This method circumvents the need for labor-intensive hand-picking, scraping, and sorting that other hESC-MSC derivation methods require. Moreover, unlike previous reports on hESC-MSCs, we have systematically evaluated their immunomodulatory properties and in vivo potency. As expected, they dynamically secrete a range of bioactive factors, display enzymatic activity, and suppress T-cell proliferation that is induced by either allogeneic cells or mitogenic stimuli. However, they also display unique immunophenotypic properties, as well as a smaller size and >30,000-fold proliferative capacity than bone marrow-derived MSCs. In addition, this is the first report which demonstrates that hESC-MSCs can inhibit CD83 up-regulation and IL-12p70 secretion from dendritic cells and enhance regulatory T-cell populations induced by interleukin 2 (IL-2). This is also the first report which shows that hESC-MSCs have therapeutic efficacy in two different autoimmune disorder models, including a marked increase in survival of lupus-prone mice and a reduction of symptoms in an autoimmune model of uveitis."

According to the news editors, the research concluded: "Our data suggest that this novel and therapeutically active population of MSCs could overcome many of the obstacles that plague the use of MSCs in regenerative medicine and serve as a scalable alternative to current MSC sources."

For more information on this research see: Mesenchymal Stem Cell Population Derived from Human Pluripotent Stem Cells Displays Potent Immunomodulatory and Therapeutic Properties. Stem Cells and Development, 2014;23(14):1611-1624. Stem Cells and Development can be contacted at: Mary Ann Liebert, Inc, 140 Huguenot Street, 3RD Fl, New Rochelle, NY 10801, USA. (Mary Ann Liebert, Inc. - www.liebertpub.com; Stem Cells and Development - www.liebertpub.com/overview/stem-cells-and-development/125/)

The news editors report that additional information may be obtained by contacting E.A. Kimbrel, University of California, David Geffen Sch Med, Div Rheumatol, Los Angeles, CA 90095, United States. Additional authors for this research include N.A. Kouris, G.J. Yavanian, J.L. Chu, Y. Qin, A. Chan, R.P. Singh, D. McCurdy, L. Gordon, R.D. Levinson and R. Lanza (see also Stem Cell Research).

Keywords for this news article include: California, Los Angeles, Therapeutics, United States, Stem Cell Research, Mesenchymal Stem Cells, Pluripotent Stem Cells, North and Central America

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters